Skorpios Trust’s Stoke Therapeutics STOK Stock Holding History

Skorpios Trust’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$53M	Sell	2,256,181 -1,000,000	-31%	-$17.1M	99.68%	1
2025 Q2	$37M	Sell	3,256,181 -3,650,000	-53%	-$34.7M	99.62%	1
2025 Q1	$45.9M	Hold	6,906,181	–	–	99.7%	1
2024 Q4	$76.2M	Sell	6,906,181 -2,000,000	-22%	-$24.6M	99.8%	1
2024 Q3	$109M	Sell	8,906,181 -1,937,500	-18%	-$27.4M	99.85%	1
2024 Q2	$146M	Sell	10,843,681 -3,600,000	-25%	-$48.6M	99.89%	1
2024 Q1	$195M	Hold	14,443,681	–	–	99.92%	1
2023 Q4	$76M	Hold	14,443,681	–	–	99.8%	1
2023 Q3	$56.9M	Hold	14,443,681	–	–	99.78%	1
2023 Q2	$154M	Hold	14,443,681	–	–	66.67%	1
2023 Q1	$120M	Hold	14,443,681	–	–	48.62%	2
2022 Q4	$133M	Hold	14,443,681	–	–	42.4%	2
2022 Q3	$185M	Hold	14,443,681	–	–	52.34%	1
2022 Q2	$191M	Hold	14,443,681	–	–	79.84%	1
2022 Q1	$304M	Hold	14,443,681	–	–	80.96%	1
2021 Q4	$347M	Buy	+14,443,681	New	+$345M	76.67%	1

Other funds holding STOK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Skorpios Trust's STOK Position: Q3 2025 in Review

Skorpios Trust reduced its Stoke Therapeutics (STOK) stake by 31% in Q3 2025, selling an estimated $17.1M and leaving 2,256,181 shares worth $53M. The position accounts for 99.68% of the portfolio, ranked #1.

Skorpios Trust first reported a position in STOK in Q4 2021 and has held it in 16 quarters since. The position peaked at $347M in Q4 2021. 151 funds tracked by Wall St. Rank hold STOK as of Q3 2025.

Skorpios Trust held 2,256,181 shares of Stoke Therapeutics worth $53M as of Q3 2025.
Skorpios Trust sold 1,000,000 Stoke Therapeutics shares in Q3 2025, an estimated $17.1M.
Stoke Therapeutics made up 99.68% of Skorpios Trust's portfolio in Q3 2025, its #1 holding.
Skorpios Trust first reported a position in Stoke Therapeutics in Q4 2021 and has held it in 16 quarters since.
Skorpios Trust's Stoke Therapeutics position peaked at $347M in Q4 2021.
151 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2025.

Based on Skorpios Trust's 13F filing for Q3 2025, filed 29 Oct 2025.